Biora Therapeutics to Attend Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO, Aug. 06, 2024 -- Biora Therapeutics, Inc. (Nasdaq: BIOR), a biotech company innovating therapeutic delivery methods, announced its participation in the upcoming Canaccord Genuity 44th Annual Growth Conference. The event is scheduled to take place from August 13 to August 15, 2024, in Boston, MA. During the conference, Biora Therapeutics will engage in both a company presentation and one-on-one meetings with investors.

Biora Therapeutics is a clinical-stage biotechnology firm that focuses on developing innovative therapeutic delivery systems. The company is currently working on two primary platforms: the NaviCap™ and the BioJet™. 

The NaviCap™ platform is designed for colon-targeted treatment of inflammatory bowel disease (IBD). This technology aims to enhance patient outcomes by delivering medication directly to the affected area in the gastrointestinal tract. The targeted delivery is intended to improve the efficacy of treatments and reduce side effects compared to traditional methods.

On the other hand, the BioJet™ platform focuses on the oral delivery of large molecules, which are typically administered via injections. This platform seeks to provide a needle-free alternative for managing chronic diseases, thereby improving patient compliance and quality of life. The oral delivery system is designed to be more convenient for patients, aligning with Biora’s goal of reimagining therapeutic delivery.

Further details about Biora Therapeutics' projects and innovations can be found on their website. Additionally, the company maintains a presence on professional social media platforms such as LinkedIn and X.

Biora Therapeutics continues to push the boundaries in the field of therapeutic delivery, with ongoing research and development efforts. The company's innovative platforms hold promise for transforming how treatments are administered, potentially leading to better patient outcomes and improved management of chronic conditions. 

As the company participates in the Canaccord Genuity 44th Annual Growth Conference, stakeholders and potential investors will have the opportunity to gain deeper insights into Biora’s strategies and progress. This engagement is part of Biora’s broader effort to collaborate with investors and other stakeholders to further its mission of enhancing therapeutic delivery.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!